AOD-9604 vs Cjc-1295 Ipamorelin: A Research Reference
Before AOD-9604 and Cjc-1295 Ipamorelin can be compared on anything else, they have to be compared on evidence: what has actually been indexed, and where.
Compound profiles
AOD-9604 in the indexed record
Searching AOD-9604 against the PubMed index returns 16 records, a limited evidence base with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in Curr Opin Investig Drugs, Drug Test Anal, Expert Rev Proteomics, spanning 2004–2026.
- AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004. PMID: 15134286
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013. PMID: 24124033
- Human sports drug testing by mass spectrometry — Mass Spectrom Rev, 2017. PMID: 26213263
Cjc-1295 Ipamorelin in the indexed record
Searching Cjc-1295 Ipamorelin against the PubMed index returns 10 records, a limited evidence base with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in Am J Sports Med, Int J Mol Sci, J Am Acad Orthop Surg Glob Res Rev.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — J Sports Med Phys Fitness, 2026. PMID: 41880199
Classification and why it matters
AOD-9604 and Cjc-1295 Ipamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for AOD-9604 describes conditions validated for AOD-9604: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Cjc-1295 Ipamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | AOD-9604 | Cjc-1295 Ipamorelin |
|---|---|---|
| PubMed indexed records | 16 | 10 |
| Registered studies (ClinicalTrials.gov) | 0 | 0 |
| Literature depth | Emerging | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. AOD-9604 carries 6 more indexed records than Cjc-1295 Ipamorelin, which means published methodology, characterisation data and replication attempts are more readily located for AOD-9604. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Selecting between them for a study design
AOD-9604 and Cjc-1295 Ipamorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (AOD-9604) generally offers more methodological precedent.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Frequently asked questions
Which of AOD-9604 or Cjc-1295 Ipamorelin has more published research?
AOD-9604, with 16 indexed PubMed records against 10.
Are AOD-9604 and Cjc-1295 Ipamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 16 indexed records for AOD-9604 and 10 for Cjc-1295 Ipamorelin.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- AOD-9604 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.